The article examines the objective, findings, and clinical context described in FDA Grants Temab-A Dual Breakthrough Status.
Approach:
CRC designation: Temab-A plus bevacizumab received designation for adults with refractory metastatic colorectal cancer previously treated with specified chemotherapy and biologic regimens.
NSCLC designation: Temab-A monotherapy received designation for previously treated adults with locally advanced or metastatic EGFR wild-type, c-Met protein–expressing, nonsquamous NSCLC.
Evidence base: The designations were based primarily on findings from the ongoing first-in-human phase 1 M21-404 trial.
Key Findings:
In a CRC dose-expansion analysis, confirmed objective response was 27% among 30 patients receiving Temab-A 2.4 mg/kg plus bevacizumab, versus 0% among 20 evaluable patients receiving trifluridine/tipiracil plus bevacizumab; the 2.0-mg/kg Temab-A combination ha…
Investigators identified 2.4 mg/kg as having the most favorable benefit-risk profile. Grade 3 or higher treatment-emergent adverse events occurred in 67% with this Temab-A combination and 65% with standard-of-care therapy.
Common adverse events with Temab-A 2.4 mg/kg plus bevacizumab included anemia (63%), nausea (60%), neutropenia (53%), fatigue (43%), and vomiting (40%). Treatment-related adverse events led to discontinuation in 3% and 10% of patients, respectively.
In a separate NSCLC dose-expansion cohort of 48 patients, grade 3 or higher treatment-emergent adverse events occurred in 63%; hematologic and gastrointestinal events were most common overall.
Interpretation:
Breakthrough Therapy Designation is intended to expedite development and review when preliminary clinical evidence suggests potential substantial improvement over available treatment on a clinically significant endpoint. It is not FDA approval; Temab-A remains investigational.
Limitations:
The evidence described comes from an ongoing phase 1 study and dose-expansion analyses.
The CRC comparison included 30 patients in the 2.4-mg/kg Temab-A group and 20 evaluable patients in the standard-of-care group; patients were not selected by c-Met expression.
The provided NSCLC results report safety findings but do not provide response or survival outcomes.
The assay is indicated to identify patients with advanced melanoma who have BRAF V600E or BRAF V600K variants and may benefit from FDA-approved targeted therapies.
